Related Experiment Video
Updated: Jun 9, 2026

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
Published on: August 22, 2017
Investigation of Metformin HCl lot-to-lot variation on flowability differences exhibited during drug product
Radha R Vippagunta1, Rosario LoBrutto, Changkang Pan
1Pharmaceutical and Analytical Development, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936, USA. radha.vippagunta@novartis.com
Abstract:
The purpose of this study was to determine the cause for flowability difference observed during drug product processing when different Metformin HCl drug substance batches of varying age were used. It was found that the lead time (age) between the final step (milling) in the manufacturing process of the Metformin HCl drug substance could be a factor. The lead time had an impact on flowability of Metformin/excipient blends during drug product processing even though these batches had no apparent differences in their release specifications. To study and understand the aging effect, two batches of Metformin HCl manufactured at different periods of time were selected. The surface energy values obtained by the density functional theory (DFT) method together with X-ray diffraction patterns, thermally stimulated current measurements, and dynamic vapor sorption isotherms indicated that the freshly manufactured Metformin HCl material contains detectable amounts of surface crystal defects, but are absent in aged sample, which could be the cause of flowability differences of Metformin/excipient blends observed during the drug product processing. Having identified the cause for different flow behavior, a method to destroy these defects was designed and the issue was resolved by rapid aging of Metformin HCl under humidity at room temperature.
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Drug Dissolution: Requirements and Profile Comparison
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
In Vitro Drug Release Testing: Overview, Development and Validation
Clinically Relevant Drug Product Specifications: Methods of Establishment
FDA Approved Drugs: Changes to Approved Drugs
